Now, why would Pfizer buy cardiovascular biopharma company?
Pfizer is about to buy Arena Pharmaceuticals for $6.7 billion. Arena is a biopharmaceutical company focused in part on cardiovascular and inflammatory medicines to a global patient cohort. A majority of mainstream news outlets have focused their reportage on Arena’s bowel disease treatment, while failing to mention the firm’s cardiovascular research.
Read full article here: thenationalpulse.com
Recommended for you
